Home
/
Travere Therapeutics, Inc.
/
Financials
/
Quarterly
Travere Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Travere Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2012
Nov 30, 2012
$0
Mar 6, 2013
Q2
2012
Aug 31, 2012
$0
Oct 10, 2012
Q1
2012
May 31, 2012
$0
Aug 8, 2012
Q3
2012
Nov 30, 2011
$0
Mar 6, 2013
Q2
2011
Aug 31, 2011
$0
Jun 6, 2012
Q1
2012
May 31, 2011
$0
Aug 8, 2012
Q3
2011
Nov 30, 2010
$0
Jan 11, 2012
Q2
2011
Aug 31, 2010
$0
Jun 6, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$164.86M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$114.45M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$81.73M
May 1, 2025
Q3
2025
Sep 30, 2024
$62.90M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$54.12M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$41.37M
May 1, 2025
Q3
2024
Sep 30, 2023
$37.10M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$32.20M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$30.89M
May 6, 2024
Q3
2023
Sep 30, 2022
$28.08M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$54.17M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$48.49M
May 4, 2023
Q3
2022
Sep 30, 2021
$68.22M
Oct 27, 2022
Q2
2022
Jun 30, 2021
$54.62M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$47.41M
May 5, 2022
Q3
2021
Sep 30, 2020
$51.14M
Oct 29, 2021
Q2
2021
Jun 30, 2020
$48.43M
Jul 29, 2021
Q1
2021
Mar 31, 2020
$47.77M
May 6, 2021
Q3
2020
Sep 30, 2019
$44.37M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$44.71M
Jul 31, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$25.71M
Oct 30, 2025
Q2
2025
Jun 30, 2025
($12.76M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($41.23M)
May 1, 2025
Q3
2025
Sep 30, 2024
($54.81M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($70.41M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($136.06M)
May 1, 2025
Q3
2024
Sep 30, 2023
$150.74M
Oct 31, 2024
Q2
2024
Jun 30, 2023
($85.63M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($86.33M)
May 6, 2024
Q3
2023
Sep 30, 2022
($69.66M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($67.03M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($75.97M)
May 4, 2023
Q3
2022
Sep 30, 2021
($35.64M)
Oct 27, 2022
Q2
2022
Jun 30, 2021
($39.01M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($53.87M)
May 5, 2022
Q3
2021
Sep 30, 2020
($22.55M)
Oct 29, 2021
Q2
2021
Jun 30, 2020
($26.07M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
$808.0K
May 6, 2021
Q3
2020
Sep 30, 2019
($36.49M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($38.70M)
Jul 31, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$24.93M
Oct 30, 2025
Q2
2025
Jun 30, 2025
($12.65M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($42.67M)
May 1, 2025
Q3
2025
Sep 30, 2024
($56.15M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($67.70M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($139.24M)
May 1, 2025
Q3
2024
Sep 30, 2023
($92.59M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($103.95M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($97.37M)
May 6, 2024
Q3
2023
Sep 30, 2022
($82.60M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($65.45M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($66.13M)
May 4, 2023
Q3
2022
Sep 30, 2021
($31.71M)
Oct 27, 2022
Q2
2022
Jun 30, 2021
($35.32M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($47.55M)
May 5, 2022
Q3
2021
Sep 30, 2020
($19.44M)
Oct 29, 2021
Q2
2021
Jun 30, 2020
($23.11M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($15.07M)
May 6, 2021
Q3
2020
Sep 30, 2019
($34.44M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($36.53M)
Jul 31, 2020